^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Non Small Cell Lung Cancer
    Drug:Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    1079 / 23 - Combination of tipifarnib with KRAS G12C inhibitors to prevent adaptive resistance

    Published date:
    03/15/2023
    Excerpt:
    ...regrowth experiments using combinations of tipifarnib with KRAS G12C inhibitors and have observed synergistic, anti-proliferative effects in KRAS G12C NSCLC cell lines as well as enhanced activity of combination in a KRAS G12C NSCLC PDX model.
    Secondary therapy:
    KRAS G12C inhibitor